• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

MGB Biopharma - Articles and news items

MGB Biopharma and FDA discuss MGB-BP-3 regulatory strategy

Industry news / 9 May 2016 / Victoria White, Digital Content Producer

MGB Biopharma presented Phase I and preclinical data together with a proposal for the further development of oral MGB-BP-3 in C. difficile infections…

MGB Biopharma completes Phase I trial of MGB-BP-3

Industry news / 8 December 2015 /

MGB-BP-3 is an antibiotic that is being developed for the potential treatment of Clostridium difficile infections…

Phase I clinical trial of oral formulation of MGB-BP-3 for treatment of Clostridium Difficile infections begins

Industry news / 21 July 2015 / Victoria White

The first group of healthy volunteers have been dosed in a Phase I clinical trial assessing the safety and tolerability of an oral formulation of MGB-BP-3…